CSPCY News and Press, CSPC Pharmaceutical Group Ltd ADR From 07/31/22

CSPC Pharma out-licensed global rights (ex-China) for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. Chengdu’s Kelun-Biotech out-licensed global rights to an ADC candidate aimed at solid tumors to MSD (Merck) in a deal worth up to $936...

Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group PR Newswire Obtains exclusive worldwide rights (outside Greater China ) to develop and...

Deals And Financings ACEA Biosciences, a San Diego company with R&D and manufacturing facilities in Hangzhou, will be acquired by Agilent (NYSE: A) for $250 million in cash (see story ). ACEA has developed the xCELLigence® cell therapy analysis device intended for academic and biop...

Profit Attributable To Shareholders Increased 41.1% to HK$1,853 Million   Innovative Drug Business Continued to Deliver Strong Growth   Common Generic Drug Business Increased Market Penetration   Bulk Drug Business   Kept Market ...